Next, to interfere with ALK2/3 activity, we used the LDN-193189 inhibitor, since it displays beneficial effects in preclinical models of diffuse intrinsic pontine glioma [38]. The gene discussed is ACVR1; the disease is diffuse intrinsic pontine glioma.